SSY Group wins approval for Indobufen tablet production in China

SSY Group Limited's board of directors has announced the company secured approval for the production and registration of Indobufen Tablets (0.2g) from the National Medical Products Administration of China. This drug, classified as a type 3 chemical drug, has also passed consistency evaluation, marking a key milestone in the group's product development.

Indobufen Tablet is primarily indicated for the treatment of ischemic cardiovascular disease, ischemic cerebrovascular disease, and venous thrombosis resulting from arteriosclerosis. It also serves as a preventative measure against thrombosis during hemodialysis. This voluntary announcement aims to keep shareholders and potential investors informed of the group's latest business advancements.

As of November 14, 2025, the board of directors comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong as executive directors, alongside non-executive director Mr. Liu Wenjun, and independent non-executive directors Mr. Wang Yibing, Mr. Chow Kwok Wai, and Mr. Jiang Guangce.